{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T07:17:41Z","timestamp":1782544661821,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KI07145"],"award-info":[{"award-number":["01KI07145"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01EO1502"],"award-info":[{"award-number":["01EO1502"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["2001-2011"],"award-info":[{"award-number":["2001-2011"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013457","name":"Center for Sepsis Control and Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.vaccine.2019.11.026","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T18:51:41Z","timestamp":1574362301000},"page":"1129-1136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia"],"prefix":"10.1016","volume":"38","author":[{"given":"Christina","family":"Forstner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6022-6827","authenticated-orcid":false,"given":"Martin","family":"Kolditz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6462-2579","authenticated-orcid":false,"given":"Miriam","family":"Kesselmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ewig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grit","family":"Barten-Neiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Witzenrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8157-2753","authenticated-orcid":false,"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.11.026_b0005","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.11.026_b0010","article-title":"Epidemiology of lower respiratory tract infections in adults","author":"Feldman","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.vaccine.2019.11.026_b0015","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0032-1310103","article-title":"The burden of pneumococcal pneumonia - experience of the German competence network CAPNETZ","volume":"66","author":"Pletz","year":"2012","journal-title":"Pneumologie"},{"key":"10.1016\/j.vaccine.2019.11.026_b0020","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","article-title":"Serotype replacement in disease after pneumococcal vaccination","volume":"378","author":"Weinberger","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.11.026_b0025","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2214-109X(16)30306-0","article-title":"Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis","volume":"5","author":"Shiri","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2019.11.026_b0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000\u201317: a prospective national observational cohort study","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.026_b0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.026_b0040","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1183\/09031936.00183614","article-title":"Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia","volume":"45","author":"Rodrigo","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vaccine.2019.11.026_b0045","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1128\/CVI.00064-12","article-title":"Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine","volume":"19","author":"Pride","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.11.026_b0050","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.vaccine.2016.03.052","article-title":"Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay","volume":"34","author":"Pletz","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.026_b0055","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.026_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131494","article-title":"Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany","volume":"10","author":"van der Linden","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.11.026_b0065","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3389\/fmicb.2016.01616","article-title":"Portuguese group for the study of streptococcal I. Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012\u20132014) despite continued reductions in other 13-valent conjugate vaccine serotypes","volume":"7","author":"Horacio","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2019.11.026_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195799","article-title":"Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England","volume":"13","author":"Southern","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.11.026_b0075","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1183\/13993003.01451-2015","article-title":"Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm","volume":"47","author":"Galanis","year":"2016","journal-title":"Sweden. Eur Respir J"},{"key":"10.1016\/j.vaccine.2019.11.026_b0080","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.026_b0085","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1016\/j.vaccine.2019.06.071","article-title":"Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006\u20132018","volume":"37","author":"Andrews","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.026_b0090","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/655828","article-title":"Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis","volume":"51","author":"Weinberger","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.026_b0095","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1183\/09031936.00050413","article-title":"Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes","volume":"43","author":"Burgos","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vaccine.2019.11.026_b0100","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/1471-2334-13-492","article-title":"High incidence of septic shock caused by Streptococcus pneumoniae serotype 3\u2013a retrospective epidemiological study","volume":"13","author":"Ahl","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.026_b0105","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.vaccine.2014.02.096","article-title":"Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults","volume":"32","author":"Grabenstein","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.026_b0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13104-016-2353-3","article-title":"Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review","volume":"10","author":"Sugimoto","year":"2017","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.vaccine.2019.11.026_b0115","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1128\/CVI.00259-14","article-title":"Association between serotype-specific antibody response and serotype characteristics in patients with pneumococcal pneumonia, with special reference to degree of encapsulation and invasive potential","volume":"21","author":"Athlin","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.11.026_b0120","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1128\/CVI.00591-15","article-title":"Capsular polysaccharide (CPS) release by serotype 3 pneumococcal strains reduces the protective effect of anti-type 3 CPS antibodies","volume":"23","author":"Choi","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.11.026_b0125","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.11.026_b0130","article-title":"A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands","author":"Gessner","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.026_b0135","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3201\/eid2407.180029","article-title":"Pediatric complicated pneumonia caused by streptococcus pneumoniae serotype 3 in 13-valent pneumococcal conjugate vaccinees, Portugal, 2010\u20132015","volume":"24","author":"Silva-Costa","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.026_b0140","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/infdis\/jiu576","article-title":"Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae","volume":"211","author":"Dagan","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.026_b0145","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00103-016-2318-7","article-title":"The competence network for community-acquired pneumonia (CAP)]","volume":"59","author":"Suttorp","year":"2016","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"10.1016\/j.vaccine.2019.11.026_b0150","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s15010-004-3107-z","article-title":"CAPNETZ-community-acquired pneumonia competence network","volume":"32","author":"Welte","year":"2004","journal-title":"Infection"},{"key":"10.1016\/j.vaccine.2019.11.026_b0155","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jinf.2016.02.010","article-title":"Community-acquired Haemophilus influenzae pneumonia\u2013New insights from the CAPNETZ study","volume":"72","author":"Forstner","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2019.11.026_b0160","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1016\/j.vaccine.2019.05.003","article-title":"Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)","volume":"37","author":"LeBlanc","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.026_b0165","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1016\/j.vaccine.2019.04.087","article-title":"Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia","volume":"37","author":"Isturiz","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.026_b0170","first-page":"1","article-title":"Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013\u201318","author":"Pick","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.vaccine.2019.11.026_b0175","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00787-17","article-title":"The alere BinaxNOW pneumococcal urinary antigen test: diagnostic sensitivity for adult pneumococcal pneumonia and relationship to specific serotypes","volume":"56","author":"Shoji","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.11.026_b0180","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/cid\/cix1066","article-title":"Pneumococcal community-acquired pneumonia detected by serotype-specific urinary antigen detection assays","volume":"66","author":"Wunderink","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.11.026_b0185","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eclinm.2018.12.007","article-title":"Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales","volume":"6","author":"Djennad","year":"2018","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2019.11.026_b0190","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1016\/j.vaccine.2017.08.007","article-title":"The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study","volume":"35","author":"Menendez","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.11.026_b0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220453","article-title":"Limited indirect effects of an infant pneumococcal vaccination program in an aging population","volume":"14","author":"van der Linden","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.11.026_b0200","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/thx.2008.109785","article-title":"New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality","volume":"64","author":"Ewig","year":"2009","journal-title":"Thorax"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1931549X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1931549X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:15:15Z","timestamp":1777536915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1931549X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0264410X1931549X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.026","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}